Psoriasis Area and Severity Index (PASI) scores (mean and SD) at baseline, week 16, and week 50 in patients who had a PASI score of ≥2

<p><b>Copyright information:</b></p><p>Taken from "Infliximab (Remicade) in the treatment of psoriatic arthritis"</p><p></p><p>Therapeutics and Clinical Risk Management 2006;2(4):389-400.</p><p>Published online Jan 2006</p><p>PMCID:PMC1936360.</p><p>© 2006 Dove Medical Press Limited. All rights reserved</p>5 at baseline. Results from the Phase III, IMPACT trial that assessed the effectiveness of infliximab for treating PsA. Copyright © 2005. Reproduced with permission from . Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). , 52:1227–36